Ptc Therapeutics (PTCT) Current Deferred Revenue (2012 - 2026)

Ptc Therapeutics' Current Deferred Revenue history runs 15 years deep, the most recent figure standing at $1.2 million for Q2 2026.

• In Q2 2026, Current Deferred Revenue fell 87.79% year-over-year to $1.2 million; the TTM figure through Jun 2026 stood at $1.2 million (down 87.79% YoY), while the FY2025 annual figure was $2.0 million, down 62.94% from the prior year.
• Current Deferred Revenue for Q2 2026 stood at $1.2 million, up from $498000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $12.8 million in Q1 2025, with the low at $214000.0 in Q1 2023.
• The 5-year median for Current Deferred Revenue is $1.4 million (2022), against an average of $3.4 million.
• The sharpest annual moves came in 2024 and 2026: Current Deferred Revenue jumped 587.27% in 2024, then sank 96.12% in 2026.
• Ptc Therapeutics' Current Deferred Revenue stood at $1.4 million in 2022, then plunged by 40.71% to $801000.0 in 2023, then surged by 587.27% to $5.5 million in 2024, then plunged by 62.94% to $2.0 million in 2025, then tumbled by 41.57% to $1.2 million in 2026.
• Business Quant data shows PTCT's Current Deferred Revenue at $1.2 million in Q2 2026, $498000.0 in Q1 2026, and $2.0 million in Q4 2025.